Loading
A phase 3 trial of Capivasertib, Fulvestrant, Palbociclib, Ribociclib and Abemaciclib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) is a phase 3 interventional study registered as NCT04862663 by AstraZeneca, with 893 participants enrolled, started 2021-05-10 and due to reach its primary completion in 2027-11-01. Interventions recorded: Capivasertib, Fulvestrant, Palbociclib, Ribociclib and Abemaciclib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Ribociclib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Capivasertib, Palbociclib, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/